| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Fisher Endocrine Laboratories, Department of Medicine, Pritzker School of Medicine, University of Chicago Chicago, Ill. 60637
Abstract
o,p'-DDD is a more potent inhibitor of the human placental 17β-hydroxysteroid dehydrogenase than any of the structural analogs, non-steroidal estrogens or anti-estrogens that have been examined. This inhibition is competitive with respect to 17β-estradiol. Both o,p'-DDD and diethylstilbesterol compete for the same binding site. (Endocrinology 89: 1407, 1971)
Footnotes
1 The abbreviations used are: o,p'-DDD, 2-(2-chlorophenyl)-2-(4-chlorophenyl)-l, 1-dichloroethane; m,p'-DDD, 2-(3-chlorophenyl)-2-(4-chlorophenyl)-1, 1-dichloroethane; p,p'-DDD, 2,2-bis(4-chlorophenyl)-l,l-dichloroethane; o,p'-DDT, 2-(2-chlorophenyl)-2-(4-chlorophenyl)-l, 1,1-trichloroethane, p,p'-DDT, 2,2-bis(4-chlorophenyl)- l,l,l-trichloroethane; p,p'-DDE, 2-(2-chlorophenyl)-2-(4-chlorophenyl)-l, 1-dichloroethylene; U-11,100A,l-(2-[p-(3)4-dihydro-6-methoxy-2-phenyl-1-naphthyl) phenoxy] ethyl) pyrrolidine hydrochloride; CI-628, l-[2-(p-[
-(p-methoxyphenyl)-βnitrostyryl] phenoxy) ethyl] pyrrolidine monocitrate.
Received May 7, 1971.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |